Biotech company Odyssey Therapeutics, Inc. has announced a $168 million Series B financing, led by global venture capital firm General Catalyst, an active investor in the healthcare sector. The proceeds are to advance Odyssey’s precision immunomodulator and oncology medicine portfolio.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,